The associations representing the European and British life science industry (AESGP, ABPI, BGMA, BIA, EBE, EFPIA, EUCOPE, EuropaBio, Medicines for Europe, PAGB, Vaccines Europe) have today launched a joint policy document on the potential impact of the United Kingdom’s exit from the European Union

14 December 2017

Today, organisations representing the life science industry in the EU […]

Europe’s life science industry urges the UK and EU27 to safeguard patients’ access to medicines with a clear transition period and a future cooperation agreement after Brexit

28 November 2017

The associations representing the European and British life science industry […]

Medicines for Europe welcomes decision on EMA relocation to Amsterdam

21 November 2017

Medicines for Europe is very glad to see the Council […]

Commission sponsored study shows Supplementary Protection Certificate (SPC) Manufacturing Waiver will create Jobs, strengthen the pharmaceutical sector and reduce medicine costs

18 October 2017

On Thursday 12 October, the Directorate-general for Internal Market, Industry, […]

Medicines for Europe announces new President, launches Access to Medicines campaign

10 October 2017

The newly elected President of Medicines for Europe – Marc-Alexander Mahl – […]

Addressing medicine shortages in Europe: Competition is crucial for patient access

29 September 2017

Generic medicines have proven to be pivotal in increasing patient […]

62% of Medicines Dispensed in Europe are Generic, according to IMS New Data

15 June 2017

Pharmaceutical industry leaders and key stakeholders from the generic, biosimilar […]

EU Semester Country Specific Recommendations: More Efficient Medicine Policies Needed for Patient Access

23 May 2017

The European Semester Country Specific Recommendations show that healthcare systems […]

Over 100 Participants Explore Opportunities to Ensure Universal Access to Health

27 April 2017

Over 100 participants explored different ways and opportunities to ensure […]

Stimulating Investment in European Generic, Biosimilar and Value Added Medicines through a Transparent Legal Environment

22 March 2017

Key authorities, eminent lawyers and industry leaders discussed today in […]

Newsroom

News about

By type

Twitter

Videos

Photos

The associations representing the European and British life science industry (AESGP, ABPI, BGMA, BIA, EBE, EFPIA, EUCOPE, EuropaBio, Medicines for Europe, PAGB, Vaccines Europe) have today launched a joint policy document on the potential impact of the United Kingdom’s exit from the European Union

14 December 2017

Europe’s life science industry urges the UK and EU27 to safeguard patients’ access to medicines with a clear transition period and a future cooperation agreement after Brexit

28 November 2017

Medicines for Europe welcomes decision on EMA relocation to Amsterdam

21 November 2017

Commission sponsored study shows Supplementary Protection Certificate (SPC) Manufacturing Waiver will create Jobs, strengthen the pharmaceutical sector and reduce medicine costs

18 October 2017

Medicines for Europe announces new President, launches Access to Medicines campaign

10 October 2017

Addressing medicine shortages in Europe: Competition is crucial for patient access

29 September 2017

62% of Medicines Dispensed in Europe are Generic, according to IMS New Data

15 June 2017

EU Semester Country Specific Recommendations: More Efficient Medicine Policies Needed for Patient Access

23 May 2017

Over 100 Participants Explore Opportunities to Ensure Universal Access to Health

27 April 2017

Stimulating Investment in European Generic, Biosimilar and Value Added Medicines through a Transparent Legal Environment

22 March 2017

Subscribe to our newsletter